Clinical trials: Pulmonary Hypertension, Interstitial Lung Disease
Interstitial Lung Disease, Fibrosis Lung
FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion
This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis. It is not known why some patients with fILD clinically deteriorate.
- Conditions
- Interstitial Lung Disease, Fibrosis Lung, Pulmonary Hypertension
- Trial name
- FIBRINOX-EXTRA (NCT06416163)
- Testing
- Prospective
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
COPD, Interstitial Pneumonia
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results.
- Conditions
- COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
- Trial name
- NCT06922916
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Pulmonary Fibrosis, Pulmonary Hypertension
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis.
- Trial name
- NCT00439543
- Testing
- Iloprost inhalation
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Interstitial Lung Disease Study Group, Korea
Pulmonary Fibrosis, Hypertension, Pulmonary
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at…
- Trial name
- STEP-IPF (NCT00517933)
- Testing
- Sildenafil Citrate
- Where
- 13 sites in United States
- Volunteers
- 180 people
- Sponsor
- Duke University
Interstitial Lung Disease, Comorbidities and Coexisting Conditions
Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease.
- Conditions
- Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence
- Trial name
- TAILI (NCT06476470)
- Where
- Taiwan
- Volunteers
- 10,000 people
- Sponsor
- Taichung Veterans General Hospital
Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease)
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (V-A)…
- Conditions
- Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease), Bronchiectasis, Lymphangioleiomyomatosis
- Trial name
- NCT02859194
- Testing
- Veno-veno-arterial ECMO
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.
Interstitial Lung Disease, Pulmonary Hypertension
The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease
Pulmonary hypertension (PH) is a common disorder among patients with interstitial lung disease (ILD). The symptoms are usually nonspecific and overlooked.
- Trial name
- NCT03396120
- Testing
- Pulmonary function test
- Where
- 2 sites in Egypt
- Volunteers
- 95 people
- Sponsor
- Assiut University
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Asthma, COPD
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis
- Trial name
- NCT04624490
- Testing
- Hyperpolarized Xe129
- Where
- United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Mario Castro, MD, MPH
Pulmonary Hypertension Due to Lung Diseases
Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
This observational real-world study aims to evaluate the longitudinal clinical outcomes of adult patients with Group 3 pulmonary hypertension (PH), associated with chronic lung diseases such as interstitial lung disease, who are…
- Trial name
- AirFly (NCT07478094)
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Pulmonary Hypertension, Pulmonary Fibrosis
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.
- Trial name
- NCT02603068
- Testing
- Oral treprostinil
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
Pulmonary Fibrosis, Pulmonary Hypertension
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure.
- Trial name
- NCT00109681
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Actelion
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Trial name
- NCT00625469
- Testing
- bosentan
- Where
- 2 sites in United States
- Sponsor
- Rajan Saggar
Hypertension, Pulmonary, Lung Diseases, Interstitial
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
- Trial name
- EFS (NCT05867914)
- Testing
- Inhaled Nitric Oxide (iNO)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Third Pole Therapeutics, Inc.
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD.
- Trial name
- NCT04691154
- Testing
- L606 inhalation suspension
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Liquidia Technologies, Inc.